DNA’s has set the following mid-term financial targets:

  • Revenue growth faster than average market growth;
  • EBITDA margin of at least 30 per cent;
  • Operative capital expenditure less than 15 per cent of net sales (excluding potential fees for spectrum licenses);
  • Net debt to EBITDA less than 2.0, which can be temporarily exceeded in case of potential attractive bolt-on in-market M&A opportunities.